Ioana We Cook we Chief and generated revenue positive Kevin the as quarter. made clinical our towards good Thanks, our We age-related spinal alliance team today on always new appointment program OpRegen very payment happy our appreciate and additional he non-core as making of And data Financial from I'm aggressive to organization. our our immediate mentioned, even cancer the monetized testing. through injury The moving significant Most our substantial I have appreciate business Lineage program on milestone we first to Kevin calls. Officer. VAC-based notably treat assets. on just has leadership degeneration quarterly also joining from is joining our on everyone. delivered under continued new you us Ioana, cord with geographic progress macular team and second its progress the our clinical operational We call that had we afternoon, dry some clinical of further execute strengthened atrophy. impact the the plan, during and
Lineage each, say I is a branch call medicine. of pioneering As new
due of platform, This cell Manufacturing improve and to put, different regenerative believe or cell use cell of off also leading might the a reach types types medicine of differentiated someday or is types Simply has cells unmet long-term safe trusts retina spinal and which dysfunctional, those number is dying approach need is we or are if be disease. patients applicable injury Our restore both be of to goal replace broad needs. own, powerful, cells. our our we therapy cord value which different many and those indications, to you not function, specific because can that large cells approach to to manufacture only to into that and lost transplant cells the body or vital and demonstrating transplants our commercialized clinical but for the trials, so current cell different becoming in they it cell their types company. been
fully directed XX approaches change same differentiated, an lifetime of endless cells from and autologous surpass Hayflick because the cells, they cell even should of is use limit, created a are our cells never were our platform with All or manufactured shelf from principle to fewer can when replicated manufacture pluripotent superior replicate ago a by the cellular with supply starting or genetic we lines approved noticed has avoids risks even of the markets manipulation, complications, material death. Simply important which where aging. true have XX scale-up, genome of pluripotent can established normal effective of cell to down the a breaks potentially quality cell human and ever ceiling. serious re-emerged far programmed generate can XX, lower the we we people our and cell to over that states and, cell lifetime means starting Hayflick every the which a decades issues therapy of off the the recently entire certain of adult single provide which greater above our programs many believe characterized programs can due specific through for NIH ask therapies promise, causing to These program therapy track have lines, XXX been and The in of our clinical increasingly Lineage even changing advance also material to news limit manufacturing. Instead times certainly before trials. and we can gene enough put or it to just with show changes, utilize area will many very commercial without cells largest cell can't only this you manipulating of But some start is be the a safety detailed to When associated questions as do our and I control, regulatory the them unexpected bit before genome which mesenchymal companies, to the ophthalmology approaches various times starting are advantage will our as natural their trials provides manufacturing cell different cells. there of or competing process compared advantages desired Lineage of course, manufacture believe companies to modify a harness cells, additional differentiation appreciated have patients. our clinical guided to a I which patient for material manufacture pathway material. only yet, cost obtain mesenchymal person. what supply from approach but the limits or us which allogeneic X,XXX Using divide adult order limit We never it of enjoys new that ourselves. start part Every you in because with continue cells cells isn't about individual the control costs with necessary. advantages, in don't of our differentiation, line directed to guided With developmental That's as a new have the are in our the this simply discover material. you you starting we steps sourcing types. how or as
some and they new uncontrollable our valuable to our to And both or establish to our either documented and we strategic attributes of candidates encouraging have of injury not the tested their even cell may of the on right, cells changing on up a cells this accomplishments to lead in of treatments. we transplants, help but quick our are the diseases case treat alliances. their to the our new to And Our five the efficacy additional only our current currently dry are has own candidate as of AMD applications are advantages as with rejection pursuing, approved needed never begin usual, These consider turn they to job review own no and OpRegen, remainder patients product or also technology cells to technology are the produce of belief continue years we'll single will, and And intended the platform of for indications which our replacing that a cord after investigate to ensure AMD now, I date, related perform treatment. without dry three doing of safety genome FDA we spinal GA expectations with ways. product through we'll opportunities any our from beyond potentially year. our address in recent in potential cancer. have generate data disease
only that cells single the which prove avoids off have limitations approaches the pathway to is dysfunctional. transplant Our that or inherent or that only our be process, not patients. certain now reverse disease times we claim be even to evidence said to approach are this just support and to pathway, might a may ones healthy to able believe to have or a be entire retina occurring replace relevant And treating a it. target wrong the halt to the I or in approaches that Replacing new mutation, target subset risks have many cell we which in may disease small patients. died of but this able be approach of slow multiple may
more XX moving has OpRegen, has is that contemplated minutes one-time times of from over clinical believe by treatment local each of as we drugs use. data or for the anesthesia, have enormous positive that in its developing has and and cascade intend forward. being in evidence believe of we to beginning as currently the date Since set Phase from with We more traditional treatment amount advantage under compliance update monthly require grown of the also We continue these our updates interim monthly terms trial provided X/Xa semi performed providing about injections. lapsed the OpRegen, an a a and convenience of improved and which updates competitors
follow-up is treated expected nine quarter. our fact, next on update patients of later at this In with all least showing months
three layer, zone, And restoration or of high retinal RPE AMD just integration suggest the out membrane These retinal were presence what of and OpRegen observed in of RPE the at specifically these remarkably, outer As therapy, findings in presence this resolution, other Tomography, cells, areas evidenced the monolayer with separate no the their occurred the I using throughout area, the three was And nuclear outcomes mentioned, by clinical this any even the assessment. restoration area. OCT. Coherence dry which And that than of of treated patients time have photoreceptors present ellipsoid layer rather manner. OpRegen. showed or patients limiting OpRegen new Optical been with atrophic baseline outer patients atrophic of not means of we cells functional cells. reported overlying previously cases external of is XX of adjacent from tissue the of dose who with the received away these placing areas received that None in four has new to integration this in cells
we rate to event finding four the way of for patient’s context restoration is our out event believe or three in clinical a the XX%. the measure significance of your of to trial. this higher demonstrated it So demonstrate course, statistical the correct rate, is easier And
three who the these to of Presentation each of the case a retinal restoration. cases, experts totality irreversible have in is this with light website. each with be of visiting has knowledge, of have GA a the therapeutic many hosted patients that dry view really is detail, intervention if area we recoverable Lineage In with of and disease retinal section durability results shown findings, adding supports portion passing AMD trials And may by single now to these listened that we only the even the in condition clinical to our not some the different degenerative company tissue the replay so one to used. day. atrophic call, treated we call that hundreds Now, and despite And having Events sponsors, been and our do of findings of right those AMD by unprecedented is encourage an discuss tissue with not
In treated post-treatment Best untreated study collected, are and or addition Cohort at improvements we at those Visual to in evidence, different a our patient OpRegen with ETDRS than patients data restoration and can patients, tool. an Meanwhile, anatomical acuity for restoration Altogether, observation, Early worsened have and the in years, restoration, further clinically This in experienced year-three which visual anatomical we GA, Diabetic standard have that collected to which on of includes AMD of and of or measurement eyes the cells to improved with belief disease. data seen the discern ability the both our BCVA dataset declined stage atrophic the Treatment microperimetry or also an all gaining more the and suspension support visits acuity in patients majority of least of the point, at outcomes exhibit also light. year-two one to indicated with reported earlier intensities patients the dry in post-treatment. patient's two visual assessment functional retinal particularly XX% XX we scale, further data meaningful reinforces have RPE that clinically generate continuing eyes. improvements significant acuity functional we And collecting visual improvement of Retinopathy of scale, the letters also now X we majority with Acuity anatomical have one Corrected months which patients stable or six is in
the and it two those watch for slow imaging the We ETDRS of have the but patient’s just But for that have we you, the trial from there is testimonials their a invite you scores simply too same structural those little on patient attention vision. benefit would a growth or also attempts failed lot our patients of our reversed time. GA, patients, realized despite actually at approaches an have and OCT Now, of have competitor’s details posted. in contrast, to we benefited recently report the website the to whom who improvement treated and atrophy. of both the We technical. of In visit and to is subtleties in slowed of not growth vision hundreds to functional
which provide as Chicago, the the the XX Annual well regular Retinal the ahead plan Ophthalmology through XX medical world, including to Academy ophthalmology addition provide, Looking important Meeting, X, place New at conferences in XXXX for in Meeting, takes year, additional October September updates meeting through OpRegen XXth November that in Of place to updates promising as the Orleans, program, largest Annual XX. the at we takes Society the Scientific this we which Annual in
reach for clinical we data We next Overall, where a are the this belief also that with can maximum which our of working the generated of which provide intend our OpRegen. provide in outcomes traditional are to-date proposed cell preparation steps of of with advisors a for year, reinforces discuss meeting the quarter pharmaceutical fourth we available in limited may further development approaches, our the restorative fail transplants FDA the to and to beyond subset RPE patients. to have to benefit biological pathways
AMD medical in OpRegen option to dry work continue the as best position need in the transplants to to race available RPE We large unmet the with address GA.
new loss directly to next are injury one-time in delivered the to into is cord paralysis a SCI $X moving cell AMD, which cells allogeneic as in enhance approved commercial care quality called and significant programs a Lineage through develop are of functions, been of motor trial injury. sponsor improvements high of lead expect Now used spinal OPCX. product. and oligodendrocyte These cost there material of late-stage patient viability process, the process the we currently OPCX, to clinical for Spinal spinal OPCX the which a injuries. cord lifetime not successfully commercial production, patient. estimated to transplant cord administration the But to our in treatments was needed and prior which an specialized are with injuries a of led has treat OPCX be approved of cord the and spinal of FDA million. progenitors, manufacturing future of no different a clinical cord dry team and Because will the development, like can spinal as for compatible by manufactured area a improvements sensory scale to
months are weeks this clinical process. product will our and execution new device options next the to In new been SCI clinical would are cord scale injury and such SCI previously of we not new with formulation. fulfilling Parenchymal demonstrate because conducting same that or is safety characteristics of the controlled will the enroll are which time activity conducting year, use. introduce to The Technologies. as with FDA any expected patients our data hurdle device. injuries, to program safety delivery Overall, Delivery have simplify parallel, initiate investigational reduce was plan with focused safety designed year that our study. preparation June across amendment to Neurgain we requirements our inject the anticipate support which a and patients. to device to us for eliminate can also operations. investigational simplifying because At the for for eligible of new and treatment but or larger support phase manufacturing to minutes will model initiate may overall on and enrollment this Advanced or an several spinal respiration. by IND steps study patient's generally few through a to stopping from study an also which And that technical clinical to within And and in support safety reduce data process the facility phase a into learned steps validate help working collaboration and injury will new clinical currently accelerate without in use already few informative intend images quarter an to to which process our scale the this as late-stage to design And benefit been trial new Spinal This injury this to only comparability And significant more manufacturing which PSD Medicine larger and cells we a that we development, Testing work, we to aid a logistics expect enrollment study patients and inject at staff, system for cord also need logistics the in a facility through a these just of are We are developed approximately this patients application We for OPCX into in preparation thaw will specialized prior. new lab will development. accommodate chronic in we of the it feedback population study we broader clinical introducing large and further who to patient for This train established with spinal a fourth costs be these our the by or intended we production provide added Therapy trials. small a the the study. formulation, range commercial in have animal the safety thaw trials, to our preclinical a the a Regenerative studies in to will from And hours received are OPCX interim system of few for spinal a this new cleared increase interaction, to same enabling are submit we the clinical program in OR, allow at next had under delivery Neurgain and any with patients patients eventually RMAT need clinical allow chronic types, the our trials. is we and enroll device to XX%. to has for administration of patient has of to that FDA be clinical maintained broadly has patients the from and GMP in an in-house manufactured FDA than FDA completing addition process scale the our formulation necessary treated plan, previously, performance in subacute center, attributes a dose specifically, drug identify material developed a enrollment a subsequent it which There easier cord new
believe entire important spinal will injury launch to successful we and the of a cord an working community for the it this be field with program is SCI on trajectory. closely So we
Phase loaded off proprietary of and Now, target many you thirdly, attack research platform clinical as cell I VACX exercised to we vaccine. and to our data UK the cancer which patients. with established induction we enhance additional will mature VAC conducted it autologous manufacture X the immuno-oncology VACX specific demonstrated is shelf not cancer responses mechanistic investigational the the deploy with cell which comprised us previously. in dendritic will which option body's move year, or results system potent from to encouraging back recall cancer long of we Last in an dendritic with and bring our eliminate. cell thereafter, obtained providing in-house then banks, immune cells tumor instruct, antigen reported about reinforcing should and immune are which in lung a cells, non-small validation trials of And and clinical VACX preliminary
highest at trials and in competitive advantages competencies provide modernizations help to VACX the VAC what successfully this will impacted further advance. prepare working fairly final study. of manufacturing on VAC partner research into and improvements and with Lineage. is this be is we the are this COVID for But making from investment programs very similar is and will responsible our did the focused patient Meanwhile, may for for enrollment, process, available design UK study to enrollment both with OPCX data additional focus which core on clinical completion to we UK, and following is future they by we Our enrolling and This reported. across still OpRegen restrictions cancer the study any anticipate manufacturing
antigen the aim VAC insert of candidates nearly being of we the producing we the a limitless carrying into the each our dendritic and which cells enhancement antigen, patient's manufacturing dendritic the As enhance flexibility cells, process, one of are to VAC any part therefore by believe theoretically number platform specific because back product distinguished capable system. the to is could immune the with one of platform
So up our opens carriers own antigens, antigens. our selected large the for this to option us cells allowing partnerships retaining while number dendritic simultaneously carefully potential by of other corporate advance companies a use as to and
exact example or glioblastoma our of collaboration implementing us an and our be Immunomic product construct a we're targeting that to strategy April, by platform provided ITI, from treatment generate whom for announced platform in As of we for first would VAC candidate ITI with Therapeutics multiforme. this derived VAC with collaborating the our novel and a proprietary antigen
for which Lineage's the plan year. As derived capitalize can believe alliances cell already technology, of is our manufacturing our $X.X and cell transplants on to receive to only recent additional approach, and us validate VAC promising partnering. These this This leverage the are our a illustrative we by for this validation to allows held tissue commercialization development. another our have million, early first platform million milestone We enter believe and require in will VAC tumors. across and the opportunities pharmaceutical an corporate and of company for local that and an our and therapies delivery and have option many treatment technology clinical strength to toward stem cells and years. in achievement privately not success support we but payment announced our engraftment. of helps includes of platform, triggered accurate we of which real Alongside provide for and stem through the achieved new early related provides in vaccine diversify we of to a retention engineering accomplishments. as engine with the of we deal we or for high I'll the the over world to Therapeutics, the first therapies to our into cell next oncology for second technical August, a we solid oncology independent with working announced it And to they of generate grade add previously Amasa agreement, advanced the for The also of continue a of this scaffold deal ITI way stem-related pipeline burden opportunity based therapeutic with an of and as subsequent entered high into regenerative to our a collaboration working the biomatrix; Amasa have development high $X.X financial the new Lineage And success represents of collaboration partnering partnerships matrix which first more to the by under without represents back, with milestones, a two material continue within with demonstrated that June, development many access therapeutic the this further programs pipeline hope placement, products. provide therapies transaction agreement, theme past agreement
Russell has from unlock to continue intellectual we and we Lineage medicine, made in seek been cell property it added establishing additions XXXX therapy and In recall, and ourselves we the in assets. tremendous you extensive from value the Microcap that will as we our reflect had to progress many June, As the feel should to portfolio, Index. regenerative have an us as leader of opportunities a as growth and from benefit the continued well cell we the Index, reported foresee that Russell will therapy. non-core These help both
our further increase corporate expand to Our I programs of an drive company's continued and internal could efforts. enhancing and strengthening liquidity capabilities. stock the generate all the we Overall, awareness of to market our have addition investors, our mission of audience own Russell a awareness of among execute our clinical believe valuable help objectives three progress, Indexes broader advancing and in and can
strategic now significant for our So Lineage financial financial has of the before with new to over and $XX you Kevin transactions. that, will turn of executed me more XX our And Cook. he than walk raising the years CFO, joining I billion Kevin financial am experience. Kevin session. brings Q&A development over operational section happy update to through And corporate capital and
